Founded in 2014, Abolis employs over 60 people whose ambition is to reinvent the future of a wide range of industries (nutrition, healthcare, cosmetics, chemicals). We leverage biotechnologies and the untapped potential of microorganisms to develop sustainable and economically viable bioproduction solutions.
Background
By combining recent advances in biology, bioinformatics, genetics and bioprocessing, Abolis reprograms microorganisms to produce molecules or proteins of interest. By modifying the design of metabolic pathways, this technology enables the creation of industrial microbial strains capable of producing the desired molecules by fermentation.
The key idea is to improve on what nature has been doing so well for millennia: biosynthesis
Description of the Products / Services /Technology
Abolis has set up a synthetic biology platform that offers companies solutions for the sustainable production (biosourced and/or biodegradable) of their new or existing molecules, in order to significantly reduce their environmental impact. Abolis is involved from the project study stage through to the start of the industrialization phase, including securing intellectual property rights.
Customer references / Collaborations / Highlights
Abolis works with several major names in cosmetics, pharmaceuticals and nutrition.
The company has been selected as part of the France Relance 2030 plan.
Staff numbers will exceed 55 by the end of 2024.
The first products based on Abolis technology will be on the market in 2025.
Collaborations sought
The company has its own research program and is constantly improving its platforms.
At the same time, Abolis establishes partnerships with industrial companies:
– to produce their molecules in a biosourced way,
– to secure their raw material supplies, by relocating production,
– to give them access to rare and/or complex molecules.
